These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 30340144)

  • 1. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada.
    Bozinoff N; DeBeck K; Milloy MJ; Nosova E; Fairbairn N; Wood E; Hayashi K
    Drug Alcohol Depend; 2018 Dec; 193():42-47. PubMed ID: 30340144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
    Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
    BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.
    Socías ME; Wood E; Kerr T; Nolan S; Hayashi K; Nosova E; Montaner J; Milloy MJ
    Drug Alcohol Depend; 2018 Aug; 189():90-95. PubMed ID: 29894910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study.
    Kennedy MC; Crabtree A; Nolan S; Mok WY; Cui Z; Chong M; Slaunwhite A; Ti L
    PLoS Med; 2022 Dec; 19(12):e1004123. PubMed ID: 36454732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receipt of Opioid Agonist Treatment in provincial correctional facilities in British Columbia is associated with a reduced hazard of nonfatal overdose in the month following release.
    McLeod KE; Buxton JA; Karim ME; Martin RE; Nosyk B; Kurz M; Scow M; Felicella G; Slaunwhite AK
    PLoS One; 2024; 19(7):e0306075. PubMed ID: 38985687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada.
    Kurz M; Dale LM; Min JE; Hongdilokkul N; Greiner L; Olley M; McLeod KE; Slaunwhite A; Nosyk B
    Addiction; 2022 May; 117(5):1353-1362. PubMed ID: 34729848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
    Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
    Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.
    Moallef S; DeBeck K; Fairbairn N; Cui Z; Brar R; Wilson D; Johnson C; Milloy MJ; Hayashi K
    Addict Sci Clin Pract; 2022 Dec; 17(1):73. PubMed ID: 36522789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Polonsky M; Marcus R; Bojko MJ; Filippovych S; Springer S; Dvoriak S; Altice FL
    Drug Alcohol Depend; 2016 Aug; 165():213-20. PubMed ID: 27370527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
    Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
    Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting.
    Mackay L; Kerr T; Fairbairn N; Grant C; Milloy MJ; Hayashi K
    Addict Sci Clin Pract; 2021 Apr; 16(1):26. PubMed ID: 33910630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
    Weicker SA; Hayashi K; Grant C; Milloy MJ; Wood E; Kerr T
    Drug Alcohol Depend; 2019 Dec; 205():107672. PubMed ID: 31706251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 28-year-old Woman With Opioid Use Disorder Delivers Healthy Baby While in Custody: Addressing Forced Detox.
    Gray J; Saia K; Walley AY
    J Addict Med; 2019; 13(3):237-240. PubMed ID: 30379779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Navigating Opioid Agonist Therapy among Young People who use Illicit Opioids in Vancouver, Canada.
    Pilarinos A; Kwa Y; Joe R; Thulien M; Buxton JA; DeBeck K; Fast D
    Int J Drug Policy; 2022 Sep; 107():103773. PubMed ID: 35780565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing characteristics and outcomes of different opioid agonist treatment modalities among opioid-dependent federal men correctional populations in Canada.
    Farrell MacDonald S; Russell C; Beauchamp T; Derkzen D; Fischer B
    Int J Drug Policy; 2022 Feb; 100():103480. PubMed ID: 34656817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada.
    Guerra-Alejos BC; Yan Y; Kurz M; Mudalige N; Min JE; Homayra F; Nosyk B
    Addiction; 2024 Aug; 119(8):1453-1459. PubMed ID: 38584294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
    Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
    Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine/naloxone associated with a reduced odds of fentanyl exposure among a cohort of people who use drugs in Vancouver, Canada.
    Young S; Hayashi K; Grant C; Milloy MJ; DeBeck K; Wood E; Fairbairn N
    Drug Alcohol Depend; 2021 Nov; 228():109006. PubMed ID: 34509737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.